U.S. market Closed. Opens in 17 hours 14 minutes

ABCL | AbCellera Biologics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.5909 - 2.7700
52 Week Range 2.3350 - 6.06
Beta 0.48
Implied Volatility 52.13%
IV Rank 78.61%
Day's Volume 2,430,190
Average Volume 1,892,537
Shares Outstanding 294,666,000
Market Cap 789,704,880
Sector Healthcare
Industry Biotechnology
IPO Date 2020-12-11
Valuation
Profitability
Growth
Health
P/E Ratio -5.06
Forward P/E Ratio 18.56
EPS -0.53
1YR Price Target 28.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 586
Country Canada
Website ABCL
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
ABCL's peers: CWBR, HEPA, RAIN, KRYS, AVRO, CVAC, RETA, VIR, PPCB, PTCT, SRPT, IOVA, MDGL, CGC
*Chart delayed
Analyzing fundamentals for ABCL we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is good and Health is strong. For more detailed analysis please see ABCL Fundamentals page.

Watching at ABCL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ABCL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙